BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

LEO Pharma Selects Freeslate Core Module 3 for Sample Preparation of Viscous Drug Formulation


11/8/2011 9:40:05 AM

SUNNYVALE, Calif. (PRWEB) November 08, 2011 -- late, Inc., the leading provider of high throughput research solutions, today announced that LEO Pharma (Ballerup, Denmark) has selected Freeslate’s Core Module 3 (CM3) high throughput research platform for evaluating solubility of drugs in various viscous formulations and for preparing samples for characterization and analysis.

The CM3 platform couples many arm and deck elements to dispense materials, mix, control temperature, and carry out analytical measurements, enabling scientists to leverage a single instrument to run an array of applications. “We’re very excited to have been selected by LEO Pharma to advance its research in dermatology and critical care,” stated John Senaldi, president and chief executive officer of Freeslate. “We’re also pleased to see our global installed base continue to grow at a rapid pace. This expansion demonstrates that companies in multiple markets recognize the value of our high throughput research solutions for their R&D organizations.”

“Our research centers around the development of viscous formulations — gels, creams and ointments — which are chemically very complex, and present researchers with a multitude of development challenges,” commented Thorsten Thormann, Director of New Products of LEO Pharma. “With the Freeslate Core Module 3 integration, we can eliminate many of these concerns because we’re able to test intricate samples in one configurable system.”

The CM3 is part of Freeslate’s portfolio of high throughput products and complementary services which allow research and development organizations to make dramatic gains in productivity and innovation.

About Freeslate

Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, energy, and consumer products industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe and Asia. For more information, visit http://www.freeslate.com.

About LEO Pharma

Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company. LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. The company has its own sales forces in 61 countries and employs more than 4,600 employees worldwide. LEO Pharma is headquartered in Denmark and is wholly owned by the LEO Foundation. For more information about LEO Pharma, visit http://www.leo-pharma.com.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES